UA110199C2 - Solid rifaximin dispersion - Google Patents

Solid rifaximin dispersion

Info

Publication number
UA110199C2
UA110199C2 UAA201206356A UAA201206356A UA110199C2 UA 110199 C2 UA110199 C2 UA 110199C2 UA A201206356 A UAA201206356 A UA A201206356A UA A201206356 A UAA201206356 A UA A201206356A UA 110199 C2 UA110199 C2 UA 110199C2
Authority
UA
Ukraine
Prior art keywords
rifaximin
relates
solid dispersion
dispersion
solid rifaximin
Prior art date
Application number
UAA201206356A
Other languages
English (en)
Ukrainian (uk)
Inventor
Shirishkumar Kulkarni
Satish Kumar Dalal
Harshal Anil Jahagirdar
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA110199(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of UA110199C2 publication Critical patent/UA110199C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA201206356A 2009-10-27 2010-10-27 Solid rifaximin dispersion UA110199C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1287KO2009 2009-10-27
PCT/IN2010/000694 WO2011051971A2 (en) 2009-10-27 2010-10-27 Solid dispersion of rifaximin

Publications (1)

Publication Number Publication Date
UA110199C2 true UA110199C2 (en) 2015-12-10

Family

ID=43922730

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201206356A UA110199C2 (en) 2009-10-27 2010-10-27 Solid rifaximin dispersion

Country Status (22)

Country Link
US (3) US20120214833A1 (ru)
EP (1) EP2493456B1 (ru)
JP (2) JP6211768B2 (ru)
KR (5) KR20140015140A (ru)
CN (2) CN113274355B (ru)
AU (2) AU2010313078A1 (ru)
CA (1) CA2778981C (ru)
CL (1) CL2012001080A1 (ru)
ES (1) ES2712080T3 (ru)
GE (1) GEP201706693B (ru)
IL (1) IL219508A (ru)
MA (1) MA33761B1 (ru)
MX (1) MX346660B (ru)
MY (1) MY177151A (ru)
NZ (1) NZ599944A (ru)
PE (1) PE20121185A1 (ru)
RU (1) RU2012121599A (ru)
SG (1) SG10201501054TA (ru)
TN (1) TN2012000195A1 (ru)
UA (1) UA110199C2 (ru)
WO (1) WO2011051971A2 (ru)
ZA (1) ZA201203226B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SG188931A1 (en) 2008-02-25 2013-04-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
KR20140015140A (ko) * 2009-10-27 2014-02-06 루핀 리미티드 리팍시민의 고형 분산물
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
AU2010339573B2 (en) 2009-12-31 2014-08-28 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
MY165086A (en) * 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
JP6076267B2 (ja) 2011-02-11 2017-02-08 サリックス ファーマスーティカルズ,リミテッド リファキシミンの形態およびその使用
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
WO2013112809A2 (en) 2012-01-25 2013-08-01 Salix Pharmaceuticals, Ltd Rifaximin derivative and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014013498A1 (en) * 2012-07-17 2014-01-23 Symed Labs Limited Amorphous coprecipitates of linezolid
US20160206564A1 (en) * 2013-09-27 2016-07-21 Ira Milton Trachtman Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
PL3546464T3 (pl) 2014-05-12 2020-11-02 Alfasigma S.P.A. Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME
ES2929768T3 (es) * 2016-09-30 2022-12-01 Salix Pharmaceuticals Inc Formas sólidas de dispersión de rifaximina
CN106491558A (zh) * 2016-12-09 2017-03-15 福建生物工程职业技术学院 盐酸阿考替胺膜控型缓释制剂及其制备方法
CN106727350A (zh) * 2016-12-28 2017-05-31 潍坊宇洋药业有限公司 一种林可霉素固体分散体制剂及其制备方法
CN109772234B (zh) 2017-11-14 2024-01-05 中国石油化工股份有限公司 用于丙烯氨氧化反应器的原料气进料系统
US10765635B2 (en) * 2018-02-06 2020-09-08 Nano Pharmaceutical Laboratories Llc Multiparticulate including pharmaceutical or probiotic active ingredients for delivery via a shelf stable liquid dosage form
JP2022548788A (ja) * 2019-09-24 2022-11-21 バウシュ ヘルス アイルランド リミテッド リファキシミン液体製剤
US20230398102A1 (en) * 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
IT1320176B1 (it) * 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
ES2798253T3 (es) * 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
CN101502513A (zh) * 2008-09-04 2009-08-12 山东淄博新达制药有限公司 一种利福昔明缓释制剂组合物及其制备方法
KR20110107806A (ko) * 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
KR20140015140A (ko) * 2009-10-27 2014-02-06 루핀 리미티드 리팍시민의 고형 분산물

Also Published As

Publication number Publication date
CN102665693A (zh) 2012-09-12
IL219508A (en) 2017-04-30
JP6211768B2 (ja) 2017-10-11
KR20140015140A (ko) 2014-02-06
IL219508A0 (en) 2012-06-28
KR20170126513A (ko) 2017-11-17
CA2778981A1 (en) 2011-05-05
US20120214833A1 (en) 2012-08-23
RU2012121599A (ru) 2013-12-10
EP2493456A2 (en) 2012-09-05
WO2011051971A2 (en) 2011-05-05
PE20121185A1 (es) 2012-09-15
KR101972354B1 (ko) 2019-04-25
GEP201706693B (en) 2017-07-10
MA33761B1 (fr) 2012-11-01
MX346660B (es) 2017-03-28
JP6234412B2 (ja) 2017-11-22
KR102456997B1 (ko) 2022-10-19
SG10201501054TA (en) 2015-04-29
AU2016213722A1 (en) 2016-08-25
CL2012001080A1 (es) 2012-11-05
TN2012000195A1 (en) 2013-12-12
JP2013508451A (ja) 2013-03-07
AU2010313078A1 (en) 2012-05-24
CN113274355B (zh) 2023-05-30
NZ599944A (en) 2015-10-30
CA2778981C (en) 2019-04-02
MX2012004954A (es) 2012-09-07
KR20200100215A (ko) 2020-08-25
CN113274355A (zh) 2021-08-20
US20140221414A1 (en) 2014-08-07
KR20210156355A (ko) 2021-12-24
EP2493456B1 (en) 2018-11-21
AU2016213722B2 (en) 2018-05-24
MY177151A (en) 2020-09-08
WO2011051971A3 (en) 2011-09-09
US20200375959A1 (en) 2020-12-03
ES2712080T3 (es) 2019-05-09
KR20190000931A (ko) 2019-01-03
ZA201203226B (en) 2012-12-27
JP2016006117A (ja) 2016-01-14

Similar Documents

Publication Publication Date Title
UA110199C2 (en) Solid rifaximin dispersion
SG178952A1 (en) Chemical compounds
GEP20146060B (en) Pyridyl inhibitors of hedgehog signalling
MX2011005934A (es) Compuestos organicos.
MX2011002966A (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
EP2494059A4 (en) USE OF METHYSULFONYLMETHANE (MSM) FOR MODULATION OF MICROBIAL ACTIVITY
NZ602544A (en) Crystalline forms of a macrolide, and uses therefor
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
MY175979A (en) Certain chemical entities, compositions and methods
NZ703064A (en) Inhibitors of hepatitis c virus
MY153915A (en) Organic compounds
NO20092476L (no) Antibakterielle polycykliske ureaforbindelser
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MY162604A (en) Heterocyclic compounds and uses thereof
GEP20135964B (en) Inhibitors of beta-secretase
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
IN2012DN00869A (ru)
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
WO2012006149A3 (en) Analogs of c5a and methods of using same
IN2012DN02793A (ru)
WO2010134827A9 (en) Extended acting oxygen generating composition for treating microbial infections
EP2344642B8 (en) Novel bacteriophage strains for the treatment of bacterial infections, especially drug resistant strains of the genus enterococcus
NZ590276A (en) Use of nifurtimox for treating giardiasis